Facebook
Twitter
LinkedIn
Forward
Addressing Unmet Needs and Disease Burden in Chronic Spontaneous Urticaria: A Clinical Escape Room Challenge
Chronic spontaneous urticaria (CSU) has unpredictable symptoms without an obvious external cause; however, the symptoms of CSU, such as hives, itching and swelling, mimic an allergic reaction, and there is often significant time spent finding an external trigger. Despite current treatment options for CSU, treatment resistance and poor symptom control remain significant challenges; only 40% of patients achieve complete symptom control with standard therapy. Emerging therapies have shown great promise for addressing various treatment challenges for CSU patients by improving symptom control and potentially more effective targeting of disease pathways. This educational activity will be presented as an online, interactive, virtual escape room that challenges learners to solve several clinical cases based on current recommendations for the management of CSU.
Target Audience
The enduring activity is designed for an audience of allergy/immunology and dermatology clinicians, including physicians, advanced practice providers, nurses and other healthcare professionals.
Learning Objectives
Upon completion of the educational activity, participants should be better able to:
- Correctly describe the clinical presentation and disease burden of CSU, as compared to other similar itch diseases.
- Critically analyze the clinical data for current and emerging agents for the management of chronic urticaria.
Room 1: Building a Thorough Understanding of CSU Disease
- Chronic urticaria subtypes and clinical presentation
- Diagnostic algorithm and differential diagnoses
- Gaps and challenges in care
Room 2: Selecting Treatment and Navigating the Evolving Therapeutic Landscape
- Clinical data for current and emerging CSU treatments
- CSU treatment standard of care
 | |
Jennifer L. Hsiao, MD |
‘This activity is provided by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm.’
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
0.5 ANCC contact hours.
NP's and PA's may be able to utilize one of the credits provided on this activity.
Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
DISCLOSURES | ||
Name | Relationship | Commercial Interest |
Jennifer L. Hsiao, MD
| Advisor | AbbVie, Acclaris, Boehringer Ingelheim, Incyte, Novartis, Sanofi, UCB |
Researcher (Investigator) | Amgen, Boehringer Ingelheim, Incyte | |
Speaker | AbbVie, Galderma, Novartis, Sanofi Regeneron, and UCB | |
Dorothy Caputo, MA, BSN, RN, VP, Healthcare CE and Operations | N/A | Nothing to disclose |
Michele Bielarski, RN (planner/reviewer) | N/A | Nothing to disclose |
AKH Inc Staff and Planners | N/A | Nothing to disclose |
Tarsus dba LiVDerm Staff and Planners | N/A | Nothing to disclose |
Disclosure
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Refer to Disclosure table in the attached front matter.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to [email protected] with your information with "Opt Out" in the subject line.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Available Credit
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 Participation
Required Hardware/software
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.